
500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

Dutch State to sell share capital of Intravacc BV
Two years after the establishment of the private company Intravacc BV (Bilthoven, The Netherlands), the sale of the former Netherlands Vaccine...

Forbion raises €1.35bn across two funds
Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Stem cell gene transfer treats IL-1 immune diseases
Dysregulation of the interleukin-1 (IL-1) pathway leads to immune diseases that can result in chronic tissue and organ inflammation. Although IL-1...